Our very own Diana Stoycheva and Peter Nestorov will be representing Scailyte at the conference at booth 16. Diana will be delivering a presentation that you won’t want to miss on the topic of “AI-Powered Identification of Neurotoxicity Predictive Cell Signature in CAR-T Cell Therapy for DLBCL” on February 28 at 4:20PM!
Continue reading
We’re thrilled to share the latest installment of our ScaiDigest series, authored by our very own Diana Stoycheva! In this volume, Diana delves into the fascinating world of autoimmune diseases, shedding light on groundbreaking research and advancements in single-cell technologies that are revolutionizing our understanding of these complex conditions.
Continue reading
In this special episode, we introduce you to Peter Evans, our Principal IT Engineer at Scailyte AG. Pete’s expertise in IT and his commitment to ensuring that our technology empowers groundbreaking discoveries is pivotal to our mission.
Continue reading
Join us as Peter Nestorov, the Founder and CEO of Scailyte shares the pivotal role of Scailyte in the healthcare revolution, and his vision for the future of our industry.
Continue reading
Scailyte will be a part of the upcoming Festival of Genomics, on January 24th and 25th, 2024, in London, UK.
Continue reading
We’re back with another exciting episode of “Inside Scailyte,” where we delve into the incredible journeys and talents of our team members. In this episode, get ready to meet Filipa Teixeira, our Business Development Associate at Scailyte.
Continue reading
Scailyte’s powerful single-cell AI platform, ScaiVision, has played a pivotal role in a groundbreaking move in the field of endometriosis. Hera Biotech is set to acquire and bring to the patients Scailyte’s endometriosis diagnostic assets, marking a significant milestone in non-surgical diagnosis of endometriosis.
Continue reading
In our inaugural episode, we are honored to introduce you to Diana Stoycheva, our Principal Expert Scientist. Diana’s expertise in immunology and immunooncology which could be considered instrumental in applying our unique proprietary AI approach to revolutionize precision medicine.
Continue reading
Happy Holidays 2023
As the holiday season approaches, we want to extend our warmest wishes to all our colleagues, clients, and friends around the world.
Whether you’re celebrating Christmas, Asara B’Tevet, Kwanzaa, Gita Mahotsav, or any other end of year holiday, may this season be filled with joy, love, and togetherness.
At Scailyte, we embrace the rich tapestry of cultures and beliefs that make our global community so vibrant. Let’s come together to appreciate our precious diversity, our shared values of innovation and collaboration in the quest of knowledge that matters to patients.
Here’s to a joyful holiday season and a New Year filled with health, prosperity, and continued success. Happy Holidays from all of us at Scailyte!
Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.
Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.
Scailyte is headed to NextGen Omics US 2024 in Boston, MA on March 21-22. Join us as we showcase our...
In our latest white paper, "AI-driven single-cell data analysis identifies a cell signature predicti...
Meet Anna Dimitrova, our Chief Financial Officer at Scailyte AG. In our latest episode of "Inside Sc...
ScaiPod's mission is clear: develop next-generation clinical biomarkers for precise immuno-oncology ...
Our very own Diana Stoycheva and Peter Nestorov will be representing Scailyte at the conference at b...
We're thrilled to share the latest installment of our ScaiDigest series, authored by our very own Di...
In this special episode, we introduce you to Peter Evans, our Principal IT Engineer at Scailyte AG. ...
Join us as Peter Nestorov, the Founder and CEO of Scailyte shares the pivotal role of Scailyte in th...
Scailyte is headed to NextGen Omics US 2024 in Boston, MA on March 21-22. Join us as we showcase our...
In our latest white paper, "AI-driven single-cell data analysis identifies a cell signature predicti...
Meet Anna Dimitrova, our Chief Financial Officer at Scailyte AG. In our latest episode of "Inside Sc...
ScaiPod's mission is clear: develop next-generation clinical biomarkers for precise immuno-oncology ...
Our very own Diana Stoycheva and Peter Nestorov will be representing Scailyte at the conference at b...
We're thrilled to share the latest installment of our ScaiDigest series, authored by our very own Di...
In this special episode, we introduce you to Peter Evans, our Principal IT Engineer at Scailyte AG. ...
Join us as Peter Nestorov, the Founder and CEO of Scailyte shares the pivotal role of Scailyte in th...
We are thrilled to announce the extension of our Series A funding, bringing the total raised amount to USD 8 million.
Continue reading
